Resources from the same session
3619 - Preliminary results from TRITON2: a phase 2 study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations
Presenter: Wassim Abida
Session: Poster Discussion session - Genitourinary tumours, prostate
Resources:
Abstract
3826 - Prospective comprehensive genomic profiling (CGP) of 3,343 primary and metastatic site prostate tumors
Presenter: Siraj Ali
Session: Poster Discussion session - Genitourinary tumours, prostate
Resources:
Abstract
3724 - Genomic profiling of circulating tumour DNA (ctDNA) and tumour tissue for the evaluation of rucaparib in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Simon Chowdhury
Session: Poster Discussion session - Genitourinary tumours, prostate
Resources:
Abstract
Poster Discussion session - Genitourinary tumours, prostate - Invited Discussant 793PD, 794PD and 795PD
Presenter: Joaquin Mateo
Session: Poster Discussion session - Genitourinary tumours, prostate
Resources:
Slides
Webcast
5578 - Detection of circulating tumor DNA in de novo metastatic castrate sensitive prostate cancer
Presenter: Werner Struss
Session: Poster Discussion session - Genitourinary tumours, prostate
Resources:
Abstract
2628 - LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT+abiraterone acetate and prednisone (AAP) or placebo (PBO)
Presenter: Nubaki Matsubara
Session: Poster Discussion session - Genitourinary tumours, prostate
Resources:
Abstract
Poster Discussion session - Genitourinary tumours, prostate - Invited Discussant 796PD and 797PD
Presenter: Joe O'Sullivan
Session: Poster Discussion session - Genitourinary tumours, prostate
Resources:
Slides
Webcast
1594 - In-depth assessment of metastatic prostate cancer with high tumour mutational burden
Presenter: Niven Mehra
Session: Poster Discussion session - Genitourinary tumours, prostate
Resources:
Abstract
1532 - Phase I dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC)
Presenter: Scott Tagawa
Session: Poster Discussion session - Genitourinary tumours, prostate
Resources:
Abstract